热搜词：
注册
登录
CN
  • CN
  • EN

产品中心 蛋白 其他

所有图片（1/1）

Human VISTA, His tag

Platelet receptor Gi24,Stress-induced secreted protein-1(Sisp-1),V-set domain-containing immunoregulatory receptor,V-set immunoregulatory receptor,C10orf54,SISP1,VISTA

价格 ￥500.00 （ 供应商现货 ： 3-5个工作日）
货号 S0A0068
规格
数量
收藏 分享
产品介绍

产品介绍 评论(0)

产品规格

  • 物种

    Human

  • 分子别名

    Platelet receptor Gi24, Stress-induced secreted protein-1(Sisp-1), V-set domain-containing immunoregulatory receptor, V-set immunoregulatory receptor, C10orf54, SISP1, VISTA

  • Accession

    Q9H7M9

  • 表达序列

    Protein sequence (Q9H7M9, Phe33-Ala194, with C-10*His) FKVATPYSLYVCPEGQNVTLTCRLLGPVDKGHDVTFYKTWYRSSRGEVQTCSERRPIRNLTFQDLHLHHGGHQAANTSHDLAQRHGLESASDHHGNFSITMRNLTLLDSGLYCCLVVEIRHHHSEHRVHGAMELQVQTGKDAPSNCVVYPSSSQDSENITAAGGGGSHHHHHHHHHH

  • 表达宿主

    HEK293

  • 分子量

    Predicted MW: 19.8 kDa Observed MW: 33-43 kDa

  • 纯度

    ＞95% by SDS-PAGE

  • 标签

    with C-10*His

  • 性状

    Lyophilized Powder

  • 缓冲体系

    Lyophilized from a 0.2 μm filtered solution of 0.2M PBS, pH7.4.

  • 溶解方法

    Reconstitute no more than 1 mg/mL according to the size in deionized water after rapid centrifugation.

  • 储存条件

    12 months from date of receipt, -20 to -70 °C as supplied. 6 months, -20 to -70 °C under sterile conditions after reconstitution. 1 week, 2 to 8 °C under sterile conditions after reconstitution. Please avoid repeated freeze-thaw cycles.

背景介绍

  • V-domain Ig suppressor of T cell activation (VISTA) is a type I transmembrane protein. VISTA belongs to the immunoglobulin superfamily and has one IgV domain. VISTA is part of the B7 family, is primarily expressed in white blood cells and its transcription is partially controlled by p53. There is evidence that VISTA can act as both a ligand and a receptor on T cells to inhibit T cell effector function and maintain peripheral tolerance. VISTA is produced at high levels in tumor-infiltrating lymphocytes, such as myeloid-derived suppressor cells and regulatory T cells, and its blockade with an antibody results in delayed tumor growth in mouse models of melanoma and squamous cell carcinoma. Monocytes from HIV-infected patients produce higher levels of VISTA compared to uninfected individuals. There is an ongoing cancer immunotherapy clinical trial for a monoclonal antibody targeting VISTA in advanced cancer. Preliminary results of the phase I clinical trial show good safety tolerance and anti-cancer activity in patients with advanced tumours.

  • 电泳

    • 2μg（R: reducing conditions）

评论(0)